FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma By Ogkologos - March 27, 2025 509 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ECHELON-3 study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR Effects of Patient Navigation, Lower-Cost Drug Alternatives on the Cost of... September 26, 2022 It Might Sound Trite But… May 11, 2021 EMA Recommends Granting a Marketing Authorisation for Plerixafor Accord November 10, 2022 Teen Helps Mom With Cancer Shave Her Head, Then Turns To... October 1, 2021 Load more HOT NEWS New on NCI’s Websites for December 2022 7 Practical Tips for Taking Long-Term Medication Durable Activity of Repotrectinib in Patients with ROS1 Fusion–Positive NSCLC Regardless... ENLACE Study Explores Colorectal Cancer in Hispanic and Latino People
